BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.

zeteletinib (BOS-172738) - Boston Pharma

http://www.ncbi.nlm.nih.gov/pubmed/40992271

A Gazzah; A Italiano; B C Cho; B Doger; B Jeglinski; H H Loong; J Trigo; J-Y Shih; K Andreas; M Keegan; P Gougis; P Schöffski; V Subbiah

Sep 25, 2025